Therapeutics Randomised controlled trial
Respiratory syncytial virus prophylaxis reduces chronic respiratory morbidity in prematurely born infants 10.1136/eb-2013-101437
Anne Greenough Division of Asthma, Allergy and Lung Biology, NICU, King’s College Hospital, King’s College London, London, UK Correspondence to: Professor Anne Greenough, Division of Asthma, Allergy and Lung Biology, NICU, King’s College Hospital, King’s College London, Denmark Hill, London, SE5 9RS, UK;
[email protected] Commentary on: Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791–9.
Context Respiratory syncytial virus (RSV) and lower respiratory tract infections (LRTIs) are associated with chronic respiratory morbidity (CRM) at follow-up. In infants born very prematurely who had bronchopulmonary dysplasia (BPD), RSV LRTIs were associated with greater lung function abnormalities and healthcare utilisation at school age.1 A prospective study2 demonstrated that among very prematurely born infants (